Occlutech AFR Heart Failure Device Obtains CE Mark Approval

Food and Healthcare Press Releases Monday September 9, 2019 09:23
SCHAFFHAUSEN, Switzerland--9 Sep--PRNewswire/InfoQuest

Occlutech AG announced today that its atrial flow regulator, the Occlutech AFR device, has obtained CE mark approval clearing it for sales on the European CE regulated market. Occlutech AFR is a next generation intra-atrial shunt device, intended to treat heart failure symptoms by decompressing abnormal intra-atrial pressure. It is placed in the septum between the left atrium and right atrium in a minimally invasive procedure. It is manufactured in different sizes thereby allowing unique patient-oriented and individualized treatment.

In Europe and around the world, millions of patients suffer from heart failure and several hundred thousand die from this condition every year. Many of these patients suffer from decreasing cardiac output that originates from a malfunction of the left heart. As a consequence, the left atrium will dilate and become volume and pressure overloaded. This leads to the most important clinical symptom of heart failure, i.e. pulmonary congestion and shortness of breath. By placing the Occlutech AFR device into the septum and creating a restrictive atrial septal opening by maintaining the correct sizing of a created shunt, the intra cardiac pressure is substantially reduced, thereby improving the heart's function.

"With CE mark approval of the Occlutech AFR we are taking another big step towards becoming a multi-franchise congenital and structural heart disease therapy provider." says Sabine Bois, Co-CEO of Occlutech AG. Additionally, she states that "the Occlutech AFR with its efficacy, versatility, convenience and safety has true potential to revolutionize the way heart failure patients are treated."

Occlutech is one of the leading companies in its field, with several major products including state-of-the-art PFO occluders, ASD occluders among others. Occlutech has sales of congenital and structural heart products in over 80 countries and maintains manufacturing and R&D facilities in Jena, Germany and Istanbul, Turkey. Occlutech has developed many novel products and technologies to improve treatment of patients in these and related areas. (www.occlutech.com)

Contact:
Sabine Bois
Co-CEO Occlutech Group
Mobile: +49-160-90792130
Email: sabine.bois@occlutech.com
Susanne Goransson
Executive Assistant
Mobile: +46-704-33-65-21
Email: susanne.goransson@occlutech.com
Logo - https://mma.prnewswire.com/media/971275/Occlutech_International_AB_Logo.jpg

Latest Press Release

Menarini: Elcin Barker Ergun Group CEO

"Elcin Barker Ergun is the ideal addition to the Menarini team, in order to continue the agenda of growth in geography and therapeutic areas," commented Eric Cornut, Chairman of Menarini. Elcin Barker Ergun: "Menarini is a company admired on a global...

Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Strekin AG (www.strekin.com), a biopharmaceutical company focused on treatments for hearing loss, announced today that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3...

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations

- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with...

Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019

- Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study - Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal...

Newly Published ROSacea COnsensus (ROSCO) Expert Recommendations Encourage Dermatologists to Upweight Burden-related Discussions, Aim For #Complete Clearance# of Symptoms and Consider Combination Therapy For Severe Patients

Experts also welcome upsurge in the adoption of a rosacea signs and symptoms ('phenotype') led approach in clinical practice and announce the launch of prototype clinical tools to support physicians to optimize rosacea management Published online in the...

Related Topics